Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Clasificación en acciones #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Precio por acción
$0.051239
Última sincronización: 2025-11-24
Capitalización bursátil
$1.38M
Cambio (1 día)
-4.48%
Cambio (1 año)
-54.57%
País
NO
Comercio BerGenBio ASA (BGBIO)

Categoría

Ratio P/S de BerGenBio ASA (BGBIO)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de BerGenBio ASA, el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de BerGenBio ASA desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE